Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial

Purpose The randomized phase III JO21095 trial compared the efficacy and safety of low-dose capecitabine plus docetaxel combination therapy (XT) versus single-agent administration of docetaxel in anthracycline-pretreated HER2-negative metastatic breast cancer. Methods Patients were randomized to eit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2017-02, Vol.161 (3), p.473-482
Hauptverfasser:	Yamamoto, Daigo, Sato, Nobuaki, Rai, Yoshiaki, Yamamoto, Yutaka, Saito, Mitsue, Iwata, Hiroji, Masuda, Norikazu, Oura, Shoji, Watanabe, Junichiro, Hattori, Satoshi, Matsuura, Yoshimasa, Kuroi, Katsumasa
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Anthracyclines Anthracyclines - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer metastasis Cancer research Cancer therapies Capecitabine - administration & dosage Care and treatment Clinical Trial Clinical trials Comparative analysis Dosage and administration Drug therapy Female Humans Medicine Medicine & Public Health Metastasis Middle Aged Neoplasm Staging Oncology Product development Quality of Life Retreatment Survival Analysis Taxoids - administration & dosage Taxoids - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!